Clinical trial · Observational
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Proseq Cancer: A Prospective Study of Comprehensive Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region. Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Haematological Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | PROBABILISTIC | 0.70 |
| Solid Tumor, Unspecified, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Intention-to-treat cohort
- description
- All patients included
Primary outcomes (1)
- measure
- The fraction (in %) of patients having a tumor molecular profiling done, for whom a molecularly "druggable" variant can be identified
- timeFrame
- 10 years
- description
- Total number of patients included for whom a molecular variant can be identified that potentially can be matched with a targeted drug, labelled for use in cancer, divided by total number of patients included having a tumor molecular profiling done.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Incurable, progressing and/or life-threatening cancer * Expected residual survival of at least 3 months * No efficient remaining standard treatment options * Patient recruited from the Region of Northern Jutland, Denmark Exclusion Criteria: * WHO Performance Status \>2 * Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment
References
Publications (2)
- BACKGROUNDLadekarl M, Nohr AK, Sonderkaer M, Dahl SC, Sunde L, Vestereghem C, Mapendano CK, Haslund CA, Pagh A, Carus A, Lorincz T, Nowicka-Matus K, Poulsen LO, Laursen RJ, Dybkaer K, Poulsen BK, Frokjaer JB, Brugmann AH, Ernst A, Wanders A, Bogsted M, Pedersen IS. Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital. Acta Oncol. 2023 Mar;62(3):261-271. doi: 10.1080/0284186X.2023.2185542. Epub 2023 Mar 11. PMID 36905645
- DERIVEDJakobsen MZ, Torp EA, Issa II, Hoholt H, Sonderkaer M, Madsen J, Christensen LM, Jorgensen MP, Nohr AK, Brondum RF, Kristensen DT, Dybkaer K, Severinsen MT, Due H. Evaluation of reference sample type for somatic variant calling in myeloid cancers. Ann Hematol. 2025 Nov;104(11):6091-6095. doi: 10.1007/s00277-025-06699-y. Epub 2025 Oct 22. PMID 41123648